Frontiers | Resistance to KRASG12C Inhibitors in Non-Small Cell Lung Cancer
Somatic Gain of KRAS Function in the Endothelium Is Sufficient to Cause Vascular Malformations That Require MEK but Not PI3K Signaling | Circulation Research
Exploiting the intrinsic misfolding propensity of the KRAS oncoprotein | PNAS
Targeting the KRAS mutation for more effective cancer treatment | MD Anderson Cancer Center
KRAS Biomarker | Colorectal Cancer Alliance
Frontiers | Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies
Targeting mutated GTPase KRAS in tumor therapies - ScienceDirect
The current state of the art and future trends in RAS-targeted cancer therapies | Nature Reviews Clinical Oncology
KRAS: feeding pancreatic cancer proliferation: Trends in Biochemical Sciences
Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells: Cell
KRAS mutation: from undruggable to druggable in cancer | Signal Transduction and Targeted Therapy
Notorious KRAS: Taking down cancer researchers' biggest foe
Partnership seeks to develop KRAS degraders for cancer therapy | Frederick National Laboratory
The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC) - ScienceDirect
KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition - eBioMedicine
Cancers | Free Full-Text | KRAS G12C Mutations in NSCLC: From Target to Resistance
IJMS | Free Full-Text | KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges
JCM | Free Full-Text | KRAS Mutations in Solid Tumors: Characteristics, Current Therapeutic Strategy, and Potential Treatment Exploration
Cancers | Free Full-Text | Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer
Targeting KRAS in Lung Cancer: The Past, Present, and Future - ILCN.org (ILCN/WCLC)
KRAS inhibitors, approved | Nature Cancer
Cancers | Free Full-Text | KRAS in NSCLC: State of the Art and Future Perspectives
Targeted Therapy for 'Undruggable' Lung Cancer Stems from Decades of UCSF Research | UC San Francisco
KRAS: Kirsten RAT Sarcoma Viral Oncogenic Homolog
KRAS - Wikipedia
Chemically modified MIR143-3p exhibited anti-cancer effects by impairing the KRAS network in colorectal cancer cells: Molecular Therapy - Nucleic Acids
